leadf
logo-loader
viewFutura Medical PLC

Futura Medical assessing commercialisation options for CBD100

Futura Medical's (LON:FUM) James Barder speaks to Proactive London's Andrew Scott following the news they've completed initial laboratory and optimisation work on its Dermasys® cannabidiol gel (CBD100). He says the studies have demonstrated highly efficient penetration of cannabidiol into and through the skin and that the results have shown its superiority to an established, marketed, comparator product. Barder adds they've now started to explore commercialisation options for CBD100.

Quick facts: Futura Medical PLC

Price: 14.5 GBX

AIM:FUM
Market: AIM
Market Cap: £35.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18

2 min read